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Screening by oﬂoxacin disk was carried out on 1158 strains of Streptococcus pneumoniae in
order to investigate the in vitro bacteriostatic activity of penicillin G, levoﬂoxacin,
moxiﬂoxacin, telithromycin, linezolid, pristinamycin and quinupristin–dalfopristin
against oﬂoxacin-intermediate and -resistant S. pneumoniae strains. It was concluded
that these new antimicrobial agents could be useful for the treatment of pneumococcal
infections caused by penicillin-sensitive and -resistant S. pneumoniae, and would repre-
sent a valid therapeutic option for patients allergic to b-lactams, should they prove to be
potent in vivo.
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Streptococcus pneumoniae is an important pathogen,
being a signiﬁcant cause of pneumonia, otitis
media, sinusitis and meningitis.
Until the late 1970s,S. pneumoniaewas susceptible
to several commonlyusedantimicrobials, including
thepenicillinsanderythromycin.Clinical resistance
topenicillinwas reported fromAustralia in1967 [1],
and multiresistance from Johannesburg in 1977 [2].
Since then, there has been a slow upward trend in
minimal inhibitory concentrations (MICs) of peni-
cillin for S. pneumoniae, resulting in an increasing
prevalence of penicillin resistance worldwide. In
1996, Baquero reported that between 10% and 50%
of S. pneumoniae strains are no longer susceptible to
penicillin [3]. The Alexander Project has previously
reported amarked increase in resistance since 1992,
and this situation continued in many countries in
1998. In addition, penicillin-resistant strains are
usually intermediate or resistant to other b-lactam
antibiotics, macrolides, co-trimoxazole and chlor-
amphenicol [4]. The older available ﬂuoroquino-
lones have limited activity against S. pneumoniae,
so they are not used as ﬁrst-line therapy for the
treatment of such infections.
The aim of this studywas to compare the in vitro
activities of antibiotics that can be used in respira-
tory infections, such as the new ﬂuoroquinolones
levoﬂoxacin and moxiﬂoxacin, the ketolide teli-
thromycin, the two streptogramins pristinamycin
and quinupristin–dalfopristin, and the oxazolidi-
none linezolid, against S. pneumoniae screened for
oﬂoxacin resistance by agar diffusion.
Screening by an oﬂoxacin disk (5 mg) was carried
out on 1158 isolates of S. pneumoniae collected by 18
clinical microbiological laboratories located in the
Rhoˆne-Alpes region of France during 1999. Ninety-
four isolates of S. pneumoniae with a diameter of
inhibition of less than 16mm were obtained from
blood cultures (17), middle ear discharges (6),
protected and unprotected pulmonary samples
(63) and other sources (8).
The strains were stored in brain–heart infusion
broth (bioMe´rieux, Marcy l’Etoile, France) plus
10% glycerol in liquid nitrogen.
The antimicrobial agents investigated were:
telithromycin, oﬂoxacin, levoﬂoxacin, quinupris-
tin–dalfopristin and pristinamycin from Aventis
(Paris, France), moxiﬂoxacin from Bayer AG
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(Wuppertal, Germany), linezolid from Pharmacia
Upjohn (Kalamazoo, MI, USA), and penicillin from
Roussel-Diamant (Paris, France). Stock solutions
were prepared according to the manufacturer’s
recommendations. MICs were determined by agar
dilution in Mueller–Hinton 2 agar (bioMe´rieux)
supplemented with 5% sheep blood (bioMe´rieux),
according to the recommendations of the Antibio-
gram Committee of the French Society of Micro-
biology (CA-SFM) [5]. S. pneumoniae ATCC 49619
was used as quality control. Plates were inoculated
with a multipoint replicator delivering approxi-
matively 104 CFU/spot and incubated overnight at
35 8C in aerobic conditions.
According to the recommendations of CA-SFM
[5], the percentage susceptibilities to each antibio-
tic were: penicillin, 42.6%; erythromycin, 48.9%;
tetracycline, 57.4%; oﬂoxacin, 0%; levoﬂoxacin,
87.2%; quinupristin–dalfopristin, 90.4%; telithro-
mycin, 97.9%; pristinamycin, 100%; and linezolid,
100% (Table 1).
The MIC50s and MIC90s of the antibiotics tested
are also noted in Table 1. According to the NCCLS
interpretative criteria for moxiﬂoxacin [6], 94% of
strains were susceptible to moxiﬂoxacin. All the
tetracycline-resistant strains (42.5%) or erythromy-
cin-resistant strains (51.1%) were susceptible to
linezolid.
In this study, although the strains were screened
for oﬂoxacin resistance by agar diffusion, moxi-
ﬂoxacin was the most potent of the ﬂuoroquino-
lones tested, with 94% of strains inhibited by
breakpoint concentrations of moxiﬂoxacin, 51%
by levoﬂoxacin, and 2% by oﬂoxacin (Table 2).
These results are in keeping with those of previous
in vitro studies showing that levoﬂoxacin and
moxiﬂoxacin are very active against S. pneumoniae
and that older ﬂuoroquinolones (such as oﬂoxacin)
are not antipneumococcal antibiotics [7,8]. Moxi-
ﬂoxacin was 32-fold more potent than oﬂoxacin;
these results are conﬁrmed by other studies [9,10].
Seven of the 13 oﬂoxacin-resistant strains were
susceptible to moxiﬂoxacin. Moxiﬂoxacin MICs
were four two-fold dilutions lower than those of
levoﬂoxacin. As oﬂoxacin resistance increased to
high levels, moxiﬂoxacin and levoﬂoxacin MICs
increased, but less than oﬂoxacinMICs. Quinolone
susceptibility was found to be unrelated to peni-
cillin susceptibility [11,12]. However, in this study,
the activities of levoﬂoxacin and moxiﬂoxacin
against penicillin-non-susceptible strains differed
slightly from their activities against penicillin-sus-
ceptible strains. TheMIC50 andMIC90 increased by
one or two dilutions against penicillin-resistant
strains, but the strains remained susceptible.
Visalli et al. [13] showed that MICs of moxiﬂox-
acin were at 0.25mg/L, independent of those of
penicillin G, whereas Weiss et al. [14] found that
the MIC90 of moxiﬂoxacin was 1mg/L against
penicillin-intermediate S. pneumoniae. In our
study, the MIC90 of levoﬂoxacin increased to
8mg/L against highly penicillin-resistant S. pneu-
moniae, in disagreement with the results of other
authors [11].
The in vitro activity of linezolid demonstrated in
this study is in agreement with the ﬁndings of
previous studies [15]. The MIC50 and MIC90 were,
respectively, 1mg/L and 2mg/L, and all the
Table 1 Susceptibility to different antibiotics of 94 strains of Streptococcus pneumoniae with an inhibition diameter to
ofloxacin <16mm
Breakpoints (mg/L)
S R
Susceptible
(%)
Intermediate
(%)
Resistant
(%)
MIC50
(mg/L)
MIC90
(mg/L)
Range
(mg/L)
Ofloxacina 1 >4 – 86.2 13.8 4 8 1 to >16
Levofloxacina 2 >4 87.2 3.2 9.6 1 4 0.5–16
Moxifloxacinb 1 4 93.6 4.3 2.1 0.12 0.25 0.06–4
Telithromycina 0.5 >2 97.9 2.1 0 <0.015 0.12 0.015–1
Pristinamicina 1 >2 100 0.0 0.0 0.25 0.5 0.12–1
Quinupristin–
dalfopristina
0.5 >2 90.4 9.6 0.0 0.5 1 0.25–4
Linezolida 2 >4 100 0.0 0.0 1 2 0.06–2
Erythromycina,c 1 >4 48.9 1.1 50.0 – – –
Tetracyclinea,c 4 >8 57.4 2.1 40.4 – – –
Penicillin Ga 0.06 >1 42.6 43.6 13.8 0.25 2 0.015–2
aCA-SFM breakpoints. bNCCLS breakpoints. cATB-Pneumo (bioMe´rieux).
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isolates were susceptible. Linezolid was equally
active against all the pneumococcal isolates, irre-
spective of their penicillin resistance, with MICs in
the range 0.5–2mg/L. Others have noted a simi-
larly narrow range [16]. As in the study of Jonhson
et al. [16], the proportion of isolates with MICs for
linezolid of 2mg/L was higher among the peni-
cillin-resistant S. pneumoniae strains than among
the penicillin-susceptible strains (18.5% versus
7.5%), but the excess was not statistically signiﬁ-
cant (P> 0.5, chi-squared test). Our study conﬁrms
telithromycin has excellent antipneumococcal
activity which has been well documented in pre-
vious studies [17,18]. The activities of quinupris-
tin–dalfopristin and pristinamycin were very
similar to those observed in other studies [19,20].
Screening on the basis of only the oﬂoxacin
inhibition zone diameter (<16mm) was not sufﬁ-
cient to classify the strains. The new ﬂuoroquino-
lones, telithromycin, linezolid and streptogramins
show great potential for the treatment of infections
caused by pneumococci, but oﬂoxacin-resistant
strains already show MIC increases for moxiﬂox-
acin and levoﬂoxacin. The surveillance of resis-
tance to ﬂuoroquinolones remains necessary.
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